Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), will present 12-month data from its COMPLIANCE 360° study at The American College of Cardiology’s (ACC's) 61 st Annual Scientific Session & Expo, McCormick Place South, in Chicago, March 24–27, 2012. The COMPLIANCE 360° study is comparing treatment of above-the-knee calcified lesions using CSI’s Diamondback™ Orbital Atherectomy System, followed by low-pressure balloon angioplasty, to balloon angioplasty alone. ACC Abstract Discussion: March 24 WHAT: Principal Investigator of the COMPLIANCE 360° study, Dr. Raymond Dattilo, St. Francis Health Center, Topeka, Kan., will present 12-month data in a poster session (Abstract Presentation #1123-37). The COMPLIANCE 360° trial is a prospective, randomized study that examines whether CSI’s Diamondback Orbital Atherectomy System can achieve satisfactory acute and long-term results without the need for stent placement. In the COMPLIANCE 360° study, 50 patients were enrolled at nine U.S. sites. The Diamondback System is a minimally invasive orbital atherectomy system indicated for use as therapy in patients with peripheral arterial disease (PAD) – blockages in leg arteries.
|WHEN:||Saturday, March 24, 9:30 a.m.|
|WHERE:||McCormick Place South, Hall A|
|WHEN:||Sunday, March 25:|
|•||12:15 p.m.: Challenges Associated with Treating Calcified Coronary Artery Disease|
|•||1:10 p.m.: Current Approach for Treating Calcified Peripheral Arterial Disease|
|WHERE:||CV Innovations Educational Forum, CV Theater, #22097McCormick Place South, Hall A2|
ABOUT PAD: PAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. More than 12 million people in the United States suffer from PAD. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States. For more information visit the company’s Website at www.csi360.com.